Stock comparison
JOHNSON & JOHNSON is 109.3x more valuable than Travere Therapeutics, Inc. by market capitalization ($663.28 B vs $6.07 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
JNJ is larger
JOHNSON & JOHNSON is 109.3x more valuable than Travere Therapeutics, Inc. by market capitalization ($663.28 B vs $6.07 B).
Market value leader
JNJ
JOHNSON & JOHNSON is 109.3x more valuable than Travere Therapeutics, Inc. by market capitalization ($663.28 B vs $6.07 B).
Revenue leader
JNJ
TVTX: $490.73M vs JNJ: $94.19B.
Profit leader
JNJ
TVTX: -$25.55M vs JNJ: $26.80B.
Margin leader
JNJ
TVTX: -5.2% vs JNJ: 28.5% net margin.
| Metric | TVTX | JNJ |
|---|---|---|
| Market cap | $6.07 B | $663.28 B |
| US-listed rank | #1282 | #16 |
| Revenue (latest FY) | $490.73M | $94.19B |
| Net income (latest FY) | -$25.55M | $26.80B |
| Net margin | -5.2% | 28.5% |
| P/E (trailing FY) | - | 24.7x |
| SEC filings | 1,230 | 990 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
JOHNSON & JOHNSON is 109.3x more valuable than Travere Therapeutics, Inc. by market capitalization ($663.28 B vs $6.07 B).
In their latest fiscal years, Travere Therapeutics, Inc. reported $490.73M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Travere Therapeutics, Inc. and JOHNSON & JOHNSON, or browse the full rankings.